Baltic State Symposiums
3rd Baltic symposium on strengthening the people-centred model of tuberculosis care for better diagnosis and treatment outcomes will be held November 23-24, 2018 in Riga, Latvia.
Curing TB entails adhering to a multidrug regimen for ⩾6 months. The public health consequences of nonadherence to TB treatment led to directly observed therapy (DOT) becoming the universal standard of care. While DOT is a best practice model for TB treatment, it is labor intensive and can itself be a barrier to effective therapy because of authoritarian treatment supervisions, inconvenience for patients etc. Daily visits to the DOT facility to be observed can be seen as a lack of trust to increase patients’ stigmatization and discrimination.
Countries and partner organizations via different study consortia are exploring options for the most efficient use of innovations in diagnosis and treatment of DR-TB. There are multiple examples available thorough out the world on DOT alternatives using patient friendly treatment adherence technologies. What will be the way forward in Baltic states?
To share the latest evidence on how to deliver people-oriented care in TB management;
To discuss successes and challenges on the implementation of the people centered model of TB and DR-TB care in the Baltic States.
Expected outcome: to develop a memorandum of understanding on how to achieve the best adapted model of care for all three Baltic countries and agree on the priority action points to achieve this goal.
Target group: clinicians in the field of TB, public health personnel, National TB program managers, policy makers, scientists, donors and patient representatives.
Symposium is organized by WHO Collaborating Centre (WHO CC) for Research and Training in Management of MDR-TB of Latvia, Centre for TB and Lung Disease of Riga East University Hospital (REUH), in collaboration with Latvian Society against Tuberculosis, Tartu University Hospital and Hospital of Lithuanian University of Health Sciences.
General sponsor of the symposium is Otsuka; co-sponsor of the symposium Johnson & Johnson.
The second Baltic symposium in 2017 was devoted to discuss, share experiences from countries, and to advocate at highest levels on using innovating technologies in diagnosis and treatment of dual M/XDR and Human immune deficiency virus (HIV) infection, including the use of ND for adults and children.
Symposium was organized by WHO Collaborating Centre (WHO CC) for Research and Training in Management of MDR-TB of Latvia, Centre for TB and Lung Disease of Riga East University Hospital (REUH), Latvian Centre of Infectious Diseases of REUH, in collaboration with non-governmental organization (NGO) “Tuberculosis Foundation of Latvia”, Tartu University Hospital, Estonian Society for Infectious Diseases, Hospital of Lithuanian University of Health Sciences, Vilnius University Hospital Santariskiu Klinikos, with support of Johnson & Johnson and Otsuka.
The first International Baltic Symposium was organized in Riga in May 2016 to scale up the use of new drugs in safe and effective manner and improve treatment outcomes for multidrug-resistant, extensively drug resistant tuberculosis (M/XDR-TB) patients.
Symposium was organized by WHO Collaborating Centre for Research and Training in Management of MDR-TB of Riga East University Hospital, Centre for TB and Lung Disease, Latvia, NGO Tuberculosis Foundation of Latvia, Tartu University Hospital Lung Clinic and Hospital of Lithuanian University of Health Sciences, with support of UAB “Johnson & Johnson”.
Interventions to increase TB treatment adherence and improved treatment outcomes among specific hard-to-reach and vulnerable population groups in Riga, Latvia 2016-2017
1 Dec, 2017
Strengthening Country MDR-TB Drug Management and Quantification” 2015-2017
1 Nov, 2017
Baltic State Symposiums
1 Jun, 2017